BridgeBio Pharma BBIO Royalty revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's royalty revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's royalty revenue — revenue?
- BridgeBio Pharma (BBIO) reported royalty revenue — revenue of $9.5M in Q1 2026.
- How has BridgeBio Pharma's royalty revenue — revenue changed year-over-year?
- BridgeBio Pharma's royalty revenue — revenue increased by 4556.9% year-over-year, from $204K to $9.5M.
- What does royalty revenue — revenue mean?
- Income earned from licensing the company's intellectual property to other organizations.
- How do you interpret royalty revenue — revenue?
- An increase indicates successful commercialization of the company's research and growing market adoption of licensed technologies, while a decrease may suggest expiring patents or lower sales performance by licensing partners.
- How does royalty revenue — revenue compare across companies?
- Biotechnology and pharmaceutical peers often report this as a high-margin revenue stream that scales as licensed drugs reach commercial maturity, often compared against total revenue to assess reliance on external partnerships.